Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: A macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: Synthetic macromolecular conjugate for selective interaction with proteins has a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, and at least one binding group and at least one further group being bound via covalent bond to the synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: Macromolecular water-soluble conjugates based on synthetic copolymers to which at least one affinity tag, at least one imaging probe, and at least one targeting ligand are bound via covalent bonds. The macromolecular conjugate may be used in identification, visualization, quantification or isolation of proteins and/or cells. The targeting ligand may be attached to the synthetic copolymer via a flexible linker.

Abstract: Synthetic macromolecular conjugate for selective interaction with proteins has a synthetic copolymer, and at least one binding group and at least one further group selected from an affinity tag and an imaging probe, and at least one binding group and at least one further group being bound via covalent bond to the synthetic copolymer. The macromolecular conjugate is suitable in particular for identification, visualization, quantification or isolation of proteins and/or cells.

Abstract: The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.

Abstract: A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly (SEQ ID. NO. 1), GlyPheGly (SEQ ID. NO. 2), GlyPheLeuGly (SEQ ID. NO. 3) and GlyLeuPheGly (SEQ ID. NO. 4), and a method of its preparation.

Abstract: The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.

Abstract: The present invention relates to the field of drug delivery nanosystems. More precisely, the present invention concerns a copolymer with advantageous properties for the outer coating of various nanoparticles. Said copolymer comprises at least three types of monomers with stealthy, coupling and therapeutic properties respectively, as well as an optional fourth type of monomers with targeting properties. The present invention also relates to core-shell or hollow shell nanoparticles coated by an external layer of the copolymer according to the invention. Several types of core-shell nanoparticles are envisaged. The invention also concerns methods for preparing said nanoparticles, as well as pharmaceutical compositions or medicaments comprising them.

Abstract: The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups.

Abstract: The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups, wherein the nucleic acid vector is a micro-organism selected from the group consisting of a virus, a bacteria or a bacteriophage, a fungus, a spore, a eukaryotic cell nucleus or other micro-organism fragment or a component containing genetic information, and wherein (a) the polymer and/or the linkages between it and the nucleic acid vector are hydrolytically, reducibly or enzymatically degradable; and/or (b) wherein each of the positively charged quaternary amino groups is linked to the polymer backbone via one or more degradable or biodegradable linkages.

Abstract: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides or their sodium salts.

Abstract: A polymeric drug in the form of a conjugate of a copolymer of N-(2-hydroxypropyl)-methacrylamide (HPMA) with doxorubicin bound to the polymer via spacers containing hydrolytically cleavable hydrazone bonds, of formula (I), wherein SP1 represents an aminoacyl spacer, x=40 to 335, y=1 to 25, consisting of from 90 to 99.5 mol. % of units of HPMA and 10 to 0.5 mol. % of doxorubicin-containing comonomeric units. The conjugate is prepared via direct copolymerization of the doxorubicin-containing monomer of formula (II) with HPMA.

Abstract: A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly, GlyPheGly, GlyPheLeuGly and GlyLeuPheGly, and a method of its preparation.

Abstract: A method for the preparation of polymeric conjugates of N-(2-hydroxypropyl)methacrylamide and a methacryloylaminoacylhydrazone of doxorubicin with pH-controlled release of the drug, comprising the following three steps of synthesis: a. preparation of a monomeric methacryloylaminoacylhydrazine, wherein the aminoacyl is derived from an amino acid or oligopeptide, by reaction of a methacryloyl halide with the respective peptide, amino acid, or a derivative thereof, and subsequent hydrazinolysis, b. synthesis of a polymeric precursor by direct copolymerization of N-(2-hydroxypropyl)methacrylamide with the methacryloylaminoacylhydrazine, and c. binding of doxorubicin to the polymeric precursor by reaction thereof with doxorubicin hydrochloride.

Abstract: The solution concerns reactive polymers and copolymers based on N-(2-hydroxypropyl)methacrylamide, which contain reactive thiazolidine-2-thione groups in side chains of the polymers or at the ends of polymer chains. The solution also includes a method of their preparation and their use for synthesis of polymer drugs and conjugates with proteins and preparation of gene delivery systems.

Abstract: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated ?-amino acids, ?-amino acids, aromatic amino acids or oligopeptides or their sodium salts.

Abstract: Synthetic polymer-based carrier vehicles for delivery of nucleic acid material to target cells in biological systems are made by self-assembly of the nucleic acid with cationic polymer material so as to condense the nucleic acid and form a polyelectrolyte complex and reacting the complex with hydrophilic polymer material which bonds to the complex forming a hydrophilic coating that stabilizes the complex and provides an outer protective steric shield. The carrier vehicles are useful for gene therapy.

Abstract: The solution pertains to hydrolytically degradable hydrophilic gels consisting of the individual chains of hydrophilic polymer interconnected with crosslinks containing the structure unit ##STR1## The method for preparation of the hydrolytically degradable gels consists in subjecting hydrophilic monomers or their mixture to the radical polymerization or copolymerization, or to copolymerization with hydrophobic monomers, in the presence of a new compound--N,O-dimethacryloylhydroxylamine--as a crosslinking agent, and, if desired, in the presence of a solvent, whereas the amount of hydrophilic monomers is 50 to 99.8 molar percent related to all monomers present.

Abstract: The solution pertains to hydrolytically degradable hydrophilic gels consisting of the individual chains of hydrophilic polymer interconnected with crosslinks containing the structure ##STR1## The method for preparation of the hydrolytically degradable gels consists in subjecting hydrophilic monomers or their mixture to the radical polymerization or copolymerization, or to copolymerization with hydrophobic monomers, in the presence of a new compound--N,O-dimethacryloylhydroxylamine--as a crosslinking agent, and, if desired, in the presence of a solvent, whereas the amount of hydrophilic monomers is 50 to 99.8 molar percent related to all monomers present.